Aktiesnakken — Juni 2013
-
To fend off its rivals, Sanofi is testing an improved version of Lantus in late-stage trials as well as a combination of the product with Lyxumia, a once-daily injection that controls blood sugar levels in a different way.
-
meditor HAR solgt. jvf meddelelse
-
-
Bliver spændende at høre til ADA den 24
-
regner med at lytte med live til webcast når Sanofi præsenterer
-
og så kom også storaktionærmeddlelsen - Meditor ejer ikke længere aktier
-
nu har vi en ren røv at trutte i
-
SL salget i 199,9 og genkøbet i 190,1 sad sq ret godt
-
om ikke andet, så er c20 pladsen allerede hjemme
-
Men også ret heldig. Satte jo SL i 187,9 og den ramte 189 i low
-
Nu sælger Credit Suisse bare lige have solgt dem de købte de sidste 14 dage for at holde kursen oppe
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind